Mitchell Galerkin
Psychiatry · Henderson, NVNPI 1467440339
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,668 of the $23,384 with a category attached, or 79.8%. Teva Pharmaceuticals USA, Inc. accounts for 61.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $19,590 and has fallen 99.5% since, to $98 in 2022. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $148.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$14K
- Otsuka America Pharmaceutical, Inc.$7K
- AbbVie$514
- Takeda Pharmaceuticals U.S.A., Inc.$444
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$233
- Lundbeck LLC$161
- plus $815 from 12 others
What the payments were for
- Speaking & faculty fees$18,66880%
- Travel & lodging$1,4056%
- Food & beverage$3,27214%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 32 | $14,352 |
| Otsuka America Pharmaceutical, Inc. | 18 | $6,865 |
| AbbVie(2 entities) | 34 | $514 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $444 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $233 |
| Lundbeck LLC | 8 | $161 |
| Neuronetics, Inc. | 2 | $157 |
| Johnson & Johnson | 9 | $131 |
| Boehringer Ingelheim | 1 | $121 |
| Alfasigma USA, Inc. | 1 | $73 |
| Shire North American Group Inc | 4 | $68 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| Bausch Health US, LLC | 3 | $57 |
| Avanir Pharmaceuticals, Inc. | 3 | $53 |
| Ironshore Pharmaceuticals Inc. | 1 | $27 |
| Almatica Pharma LLC | 1 | $22 |
| Alkermes, Inc. | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$14,073
- REXULTI$6,566
- NEUROSTAR TMS THERAPY$113
How this compares
$23,384 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $256 |
| Mirtazapine | 26 | $167 |
| Bupropion XlBupropion Hcl | 12 | $160 |
| Alprazolam | 28 | $136 |
| Buspirone Hcl | 13 | $124 |
| Fluoxetine Hcl | 16 | $110 |
| Quetiapine Fumarate | 11 | $108 |
| Aripiprazole | 13 | $105 |
| Clonazepam | 12 | $89 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Henderson
- Dodge SlagleHenderson$27K
- Josil GeorgeHenderson$3K
- Jonathan StillHenderson$3K
- Mark SuhanyHenderson$2K
- Leo GallofinHenderson$2K
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.